Analysts think ALKS stock price could increase by 61%
Aug 06, 2025, 11:26 AM
8.80%
What does ALKS do
Alkermes Plc is a biopharmaceutical company based in Dublin, focused on developing treatments for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, employing 2,100 people. Its key products include LYBALVI, ARISTADA, and VIVITROL, with ongoing development for neurological disorders and cancer.
18 analysts think ALKS stock price will increase by 61.11%. The current median analyst target is $42.84 compared to a current stock price of $26.59. The lowest analysts target is $30.30 and the highest analyst target is $56.70.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
